Silverarc Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Silverarc Capital Management’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-288,042	Closed	-$1.41M	–	96
2021 Q3	$1.41M	Sell	288,042 -250,702	-47%	-$1.22M	0.8%	44
2021 Q2	$2.85M	Buy	538,744 +16,155	+3%	+$83.6K	1.27%	27
2021 Q1	$2.51M	Buy	522,589 +81,634	+19%	+$426K	1.37%	28
2020 Q4	$1.91M	Buy	+440,955	New	+$1.89M	1.11%	34

Silverarc Capital Management's ADMS Position: Q4 2021 in Review

Silverarc Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 288,042 shares — an estimated $1.41M sold.

Silverarc Capital Management first reported a position in ADMS in Q4 2020 and held it in 4 quarters. The position peaked at $2.85M in Q2 2021. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

Silverarc Capital Management reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Silverarc Capital Management sold 288,042 Adamas Pharmaceuticals shares in Q4 2021, an estimated $1.41M.
Silverarc Capital Management first reported a position in Adamas Pharmaceuticals in Q4 2020 and held it in 4 quarters.
Silverarc Capital Management's Adamas Pharmaceuticals position peaked at $2.85M in Q2 2021.
0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Silverarc Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.